Pharmaceutical firms urged to report alleged anomalies in FDA

By Ma. Teresa Montemayor

November 22 2022, 4:37 pm

MANILA – Pharmaceutical companies are urged to report alleged anomalies in the Food and Drug Administration (FDA).

This, after Senator Raffy Tulfo claimed in a Senate hearing last Nov. 18 that some FDA officials are asking PHP5 million to PHP20 million from pharmaceutical companies for the fast-tracking of their products’ Certificate of Product Registration (CPR).

In a media briefing, Department of Health (DOH) officer-in-charge Maria Rosario Vergeire said upon the presentation of evidence, the DOH would probe into the FDA's alleged illegal activities.

She added that the DOH is open to discuss issues concerning FDA since it is under the Office of the Health Secretary.

“But, we request also that if this pharmaceutical company really have evidence to provide, please submit it to the Office of the Secretary so that we can be able to investigate it at once and we can address it and provide appropriate measures against those who are in violation,” she said.

“Hanggang hindi nakikita ang ebidensya, hanggat hindi naiimbestigahan, ‘di tayo makapagbigay ng (Until we don’t see any evidence, we cannot cannot conduct an investigation and provide) judgment on this,” she said. (PNA)